Atlanta, Georgia
Alzheimer's disease clinical trials in Atlanta, GA
13 Alzheimer's disease studies are recruiting participants at sites in Atlanta as of November 16, 2026, according to ClinicalTrials.gov. Clinical Trials for Alzheimer's Disease can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Atlanta at a glance
- 13 studies are recruiting at a site in Atlanta.
- By phase: Phase 1 (1), Phase 2/3 (3), Phase 3 (5), No phase (4). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (7), university, hospital or other (6).
- Most recent update to one of these records: November 16, 2026.
Studies recruiting in Atlanta
Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- Phase 3
- Ages 50 to 90
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Grady Memorial Hospital
- Registry record
- NCT07177352 · updated
Adaptango Performance PRocess for Older Adults Community reHabilitation
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- Emory University
- Study site
- Emory University, Executive Park, Wesley Woods
- Registry record
- NCT07824128 · updated
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Study site
- Agile Clinical Research Trials, LLC
- Registry record
- NCT05980949 · updated
ACP-204 in Adults With Alzheimer's Disease Psychosis
- Phase 2/3
- Ages 55 to 95
- All sexes
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Study site
- Agile Clinical Research Trials LLC
- Registry record
- NCT06159673 · updated
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Agile Clinical Research Trials, LLC
- Registry record
- NCT07011745 · updated
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Study site
- Agile Clinical Research Trials, LLC
- Registry record
- NCT06585787 · updated
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eidos Therapeutics, a BridgeBio company
- Study site
- Emory University School of Medicine
- Registry record
- NCT06563895 · updated
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Washington University School of Medicine
- Study site
- Emory University
- Registry record
- NCT05552157 · updated
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Washington University School of Medicine
- Study site
- Emory University
- Registry record
- NCT06647498 · updated
Moving Yourself in Space and Time: MYSTIC
- No phase
- Ages 18 to 79
- All sexes
- Sponsor
- Emory University
- Study site
- Emory University, Executive Park, Wesley Woods
- Registry record
- NCT07697664 · updated
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
- Phase 1
- Ages 45 to 85
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Atlanta Center of Medical Research
- Registry record
- NCT06657768 · updated
Inspiring Seniors Towards Exercise Promotion to Protect Cognition
- No phase
- Ages 65 and older
- All sexes
- Sponsor
- Emory University
- Study site
- Emory University
- Registry record
- NCT06496425 · updated
Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease
- No phase
- Ages 50 to 90
- All sexes
- Sponsor
- Emory University
- Study site
- Emory Rehabilitation Hospital
- Registry record
- NCT06484244 · updated
Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in Atlanta, GA on ClinicalTrials.gov.
Ask about studies near Atlanta
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Clinical Trials for Alzheimer's Disease does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections